152 related articles for article (PubMed ID: 6519151)
1. Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.
Ho PC; Bourne DW; Triggs EJ; Heazlewood V
Eur J Clin Pharmacol; 1984; 27(4):441-6. PubMed ID: 6519151
[TBL] [Abstract][Full Text] [Related]
2. Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone.
Ho PC; Bourne DW; Triggs EJ; Smithurst BA
Eur J Clin Pharmacol; 1984; 27(4):435-9. PubMed ID: 6519150
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.
Krause W; Karras J; Seifert W
Eur J Clin Pharmacol; 1983; 25(4):449-53. PubMed ID: 6653638
[TBL] [Abstract][Full Text] [Related]
4. The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone.
Platt D; Abshagen U; Mühlberg W; Horn HJ; Schmitt-Rüth R; Vollmar J
Arch Gerontol Geriatr; 1984 Jul; 3(2):147-59. PubMed ID: 6476975
[TBL] [Abstract][Full Text] [Related]
5. Is canrenone the major metabolite of spironolactone?
Merkus FW
Clin Pharm; 1983; 2(3):209-10. PubMed ID: 6883952
[No Abstract] [Full Text] [Related]
6. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
Vergin H; Nuss U; Strobel K
Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
[TBL] [Abstract][Full Text] [Related]
7. [Bioavailability studies of two spironolactone-preparations (author's transl)].
Vergin H; Nuss U; Schwarzländer F; Strobel K; Weigand W; Hitzenberger G
Arzneimittelforschung; 1981; 31(9):1498-503. PubMed ID: 7197963
[TBL] [Abstract][Full Text] [Related]
8. Enhancement by food of canrenone bioavailability from spironolactone.
Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
[TBL] [Abstract][Full Text] [Related]
9. Application of a simple fluorometric method on absorption of canrenone.
Radó JP; Szende L; Takó J; Nagy O; Kozma C
Int J Clin Pharmacol Biopharm; 1976 Mar; 13(2):123-6. PubMed ID: 1254376
[TBL] [Abstract][Full Text] [Related]
10. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
Krause W; Karras J; Jakobs U
J Chromatogr; 1983 Oct; 277():191-9. PubMed ID: 6643605
[TBL] [Abstract][Full Text] [Related]
11. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
[TBL] [Abstract][Full Text] [Related]
12. New insights into the pharmacokinetics of spironolactone.
Overdiek HW; Hermens WA; Merkus FW
Clin Pharmacol Ther; 1985 Oct; 38(4):469-74. PubMed ID: 4042530
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.
Karim A; Zagarella J; Hutsell TC; Dooley M
Clin Pharmacol Ther; 1976 Feb; 19(2):177-82. PubMed ID: 1261155
[TBL] [Abstract][Full Text] [Related]
14. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
[TBL] [Abstract][Full Text] [Related]
15. Ring D oxygenated Spirolactones. Characterization of human metabolic product of spironolactone.
Chinn LJ; Brown EA; Mizuba SS; Karim A
J Med Chem; 1977 Mar; 20(3):352-5. PubMed ID: 845867
[TBL] [Abstract][Full Text] [Related]
16. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.
Gardiner P; Schrode K; Quinlan D; Martin BK; Boreham DR; Rogers MS; Stubbs K; Smith M; Karim A
J Clin Pharmacol; 1989 Apr; 29(4):342-7. PubMed ID: 2723123
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours.
Merkus FW; Overdiek JW; Cilissen J; Zuidema J
Clin Exp Hypertens A; 1983; 5(2):239-48. PubMed ID: 6831747
[No Abstract] [Full Text] [Related]
18. [Aspects of the physiologic bioavailability of spironolactone and canrenone].
Portal A; Gaillot J; Bieder A; Rodary C; Bertharion JJ
Sem Hop Ther; 1976 Nov; 52(9):465-70. PubMed ID: 1006321
[No Abstract] [Full Text] [Related]
19. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
[TBL] [Abstract][Full Text] [Related]
20. Spironolactone. I. Disposition and metabolism.
Karim A; Zagarella J; Hribar J; Dooley M
Clin Pharmacol Ther; 1976 Feb; 19(2):158-69. PubMed ID: 1261153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
